1,476 results on '"Hendlisz A"'
Search Results
152. Buschke-Löwenstein tumor in a human immunodeficiency virus-positive patient : a case report and short literature review
- Author
-
Ledouble, V, primary, Sclafani, F, additional, Hendlisz, A, additional, Gomez Galdon, M, additional, and Liberale, G, additional
- Published
- 2021
- Full Text
- View/download PDF
153. Fortnightly or fractionated weekly docetaxel–cisplatin–5‐FU as first‐line treatment in advanced gastric and gastroesophageal junction adenocarcinoma: The randomized phase II DoGE study
- Author
-
Deleporte, Amélie, primary, Van den Eynde, Marc, additional, Forget, Frédéric, additional, Holbrechts, Stéphane, additional, Delaunoit, Thierry, additional, Houbiers, Ghislain, additional, Kalantari, Hassan R., additional, Laurent, Stéphanie, additional, Vanderstraeten, Erik, additional, De Man, Marc, additional, Vergauwe, Philippe, additional, Clausse, Marylene, additional, Van Der Auwera, Jacques, additional, D’Hondt, Lionel, additional, Pierre, Pascal, additional, Ghillemijn, Bjorn, additional, Covas, Angelique, additional, Paesmans, Marianne, additional, Ameye, Lieveke, additional, Awada, Ahmad, additional, Sclafani, Francesco, additional, and Hendlisz, Alain, additional
- Published
- 2021
- Full Text
- View/download PDF
154. Prognostic value of baseline and early changes of circulating-free (cf) and circulating tumor (ct) DNA in the neoadjuvant (NA) setting of early stage colon cancer (CC).
- Author
-
Bregni, Giacomo, primary, Senti, Chiara, additional, Vandeputte, Caroline, additional, Acedo Reina, Elena, additional, Gkolfakis, Paraskevas, additional, Van Laethem, Jean-Luc, additional, Vergauwe, Philippe, additional, Van Den Eynde, Marc, additional, Janssens, Jos, additional, Demolin, Gauthier, additional, Holbrechts, Stephane, additional, Clausse, Marylene, additional, De Grez, Thierry, additional, D'Hondt, Lionel A., additional, Geboes, Karen Paula, additional, Besse-Hammer, Tatiana, additional, Rothe, Francoise, additional, Flamen, Patrick, additional, Hendlisz, Alain, additional, and Sclafani, Francesco, additional
- Published
- 2021
- Full Text
- View/download PDF
155. Editorial: Radioembolization for metastatic colorectal cancer: towards maturity, at last?
- Author
-
Hendlisz, Alain, primary and Sclafani, Francesco, additional
- Published
- 2021
- Full Text
- View/download PDF
156. Total neoadjuvant therapy for rectal cancer: Making sense of the results from the RAPIDO and PRODIGE 23 trials
- Author
-
Giunta, E.F., primary, Bregni, G., additional, Pretta, A., additional, Deleporte, A., additional, Liberale, G., additional, Bali, A.M., additional, Moretti, L., additional, Troiani, T., additional, Ciardiello, F., additional, Hendlisz, A., additional, and Sclafani, F., additional
- Published
- 2021
- Full Text
- View/download PDF
157. Editorial introductions
- Author
-
Klastersky, Jean, Blay, Jean-Yves, Hindi, Nadia, Hendlisz, Alain, and Sclafani, Francesco
- Published
- 2024
- Full Text
- View/download PDF
158. Subgroup analyses of patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line (1L) therapy:Two-year clinical update
- Author
-
M. Luisa Limon, Eric Van Cutsem, Massimo Aglietta, Usman Shah, Gabriele Luppi, Pilar García-Alfonso, Ka Yeung Mark Wong, Dana Backlund Cardin, Arteid Memaj, Michael J. Overman, Heinz-Josef Lenz, Vittorina Zagonel, Jing Yang, Bart Neyns, Sara Lonardi, Tomislav Dragovich, Alain Hendlisz, Medical Oncology, Clinical sciences, Laboratory of Molecular and Medical Oncology, and Laboratory of Molecullar and Cellular Therapy
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Colorectal cancer ,business.industry ,First line ,Low dose ,Microsatellite instability ,Ipilimumab ,medicine.disease ,03 medical and health sciences ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,DNA mismatch repair ,Nivolumab ,business ,neoplasms ,030215 immunology ,medicine.drug - Abstract
58 Background: In the phase 2 CheckMate 142 trial, NIVO + low-dose IPI had robust, durable clinical benefit and was well tolerated as 1L therapy for MSI-H/dMMR mCRC (median follow-up, 29.0 months [range, 24.2–33.7]) (Lenz et al. J Clin Oncol 2020;38:Abstract 4040; NCT02060188). Objective response rate (ORR) per investigator (INV) was achieved in 69% of pts (95% CI, 53–82); progressive disease rate was 13%. Median progression-free survival (PFS) and overall survival (OS) were not reached. Median duration of treatment was 19.1 months (95% CI, 11.1–29.0). Grade 3–4 treatment-related adverse events (TRAEs) occurred in 22% of pts. We present the post hoc subgroup analyses of efficacy and safety outcomes in pts from the same follow-up based on demographics and baseline disease characteristics. Methods: Pts with MSI-H/dMMR mCRC and no prior treatment for metastatic disease received NIVO 3 mg/kg Q2W + low-dose IPI 1 mg/kg Q6W until disease progression or discontinuation. ORR (primary endpoint, RECIST v1.1) and PFS were assessed per INV. Post hoc subgroup analyses of efficacy (by ECOG performance status [PS], stage at initial diagnosis, primary tumor location, and BRAF/KRAS mutation status) and safety (by age and ECOG PS) are presented. Results: Among 45 treated pts, efficacy (Table) and safety were generally consistent across evaluated subgroups. ORR was similar in pt subgroups by BRAF/ KRAS mutation status, stage at initial diagnosis, primary tumor location, and ECOG PS (Table). Median PFS and OS were not reached (NR) in evaluated subgroups after a minimum follow-up of 24.2 months (Table). Incidence of grade 3–4 TRAEs for subgroups by age and ECOG PS were consistent with the overall population. Conclusions: NIVO + low-dose IPI demonstrated robust, durable clinical benefit; was well tolerated with 2-year follow-up; and was consistent in evaluated subgroups in 1L MSI-H/dMMR mCRC. Clinical trial information: NCT02060188. [Table: see text]
- Published
- 2021
159. 505TiP REGINA: A phase II trial of neoadjuvant regorafenib (rego) in combination with nivolumab (nivo) and short-course radiotherapy (SCRT) in intermediate-risk, stage II-III rectal cancer (RC)
- Author
-
Karel Geboes, Gabriel Liberale, Javier Carrasco, M. Van den Eynde, Giacomo Bregni, Chiara Senti, Amélie Deleporte, Yeter Gokburun, P. Demetter, Alain Hendlisz, E. Acedo Reina, Monika Peeters, Francesco Sclafani, A. Veron, Luigi Moretti, Philippe Vergauwe, Paraskevas Gkolfakis, Marc Buyse, J-L. van Laethem, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Service d'oncologie médicale, and UCL - (SLuc) Service d'hépato-gastro-entérologie
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,Colorectal cancer ,Hematology ,Stage ii ,medicine.disease ,chemistry.chemical_compound ,chemistry ,Internal medicine ,Regorafenib ,Medicine ,Nivolumab ,business ,Intermediate risk ,Short course radiotherapy - Abstract
Background Despite recent improvements, management of locally advanced rectal cancer (LARC) remains challenging, and many patients (pts) still experience recurrence. In preclinical models, combining Rego with an anti-PD-1 inhibitor led to superior tumour growth suppression as compared with either treatment alone. In a phase I clinical trial, remarkable results were reported for the combination of Rego and Nivo in advanced MSS colorectal cancer. This synergistic effect is thought to be secondary to the anti-angiogenic effects of Rego and its potential to reduce TAMs, promote M1 macrophage conversion, and downregulate expression of immunosuppressive factors. Building on these data, we designed a trial of Rego-Nivo with standard SCRT in the neoadjuvant setting of RC. Trial design REGINA is an academic, multicentre, single-arm, phase II trial sponsored by Institut Jules Bordet. Eligible patients are treated according to the following plan: induction phase (Nivo 240 mg IV D1&15, and Rego 80 mg PO D1-14), SCRT (D22-26), consolidation phase (Nivo 240 mg IV D29,43&57, and Rego 80 mg PO D29-49), and surgery (7-8 weeks after SCRT). Key eligibility criteria include age ≥18 years, ECOG PS ≤1, adenocarcinomas below the peritoneal reflection, intermediate-risk, stage II-III tumour (ie, cT3/T4aNany or cT1-2N+, no involvement/threatening of the mesorectal fascia, no involvement of lateral pelvic lymph nodes). The primary endpoint is pathological complete response (pCR). Secondary endpoints include, among others, toxicity, compliance to treatment, pTRG, event-free survival, and overall survival. The study follows a Simon’s two-stage design (null hypothesis pCR=12%, alternative hypothesis pCR=24%; α=5%, β=20%) with a maximum of 60 pts to be enrolled. A safety interim analysis is planned after the first 6 pts have completed treatment. Serial collection of tumour, blood, and stool samples is mandatory at pre-specified time points for exploratory correlative biomarker analyses. The trial is planned to be run at 8-10 centres across Belgium. Study recruitment started in Q1 2021 and is anticipated to complete in Q3 2023. Clinical trial information: NCT04503694.
- Published
- 2021
160. sj-docx-1-tam-10.1177_17588359211045860 – Supplemental material for Isotoxic high-dose stereotactic body radiotherapy integrated in a total multimodal neoadjuvant strategy for the treatment of localized pancreatic ductal adenocarcinoma
- Author
-
Bouchart, Christelle, Engelholm, Jean-Luc, Closset, Jean, Navez, Julie, Loi, Patrizia, Gökburun, Yeter, De Grez, Thierry, Mans, Laura, Hendlisz, Alain, Bali, Maria Antonietta, Eisendrath, Pierre, Van Gestel, Dirk, Hein, Matthieu, Moretti, Luigi, and Van Laethem, Jean-Luc
- Subjects
110203 Respiratory Diseases ,FOS: Clinical medicine ,111702 Aged Health Care ,FOS: Health sciences ,111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified ,111299 Oncology and Carcinogenesis not elsewhere classified - Abstract
Supplemental material, sj-docx-1-tam-10.1177_17588359211045860 for Isotoxic high-dose stereotactic body radiotherapy integrated in a total multimodal neoadjuvant strategy for the treatment of localized pancreatic ductal adenocarcinoma by Christelle Bouchart, Jean-Luc Engelholm, Jean Closset, Julie Navez, Patrizia Loi, Yeter Gökburun, Thierry De Grez, Laura Mans, Alain Hendlisz, Maria Antonietta Bali, Pierre Eisendrath, Dirk Van Gestel, Matthieu Hein, Luigi Moretti and Jean-Luc Van Laethem in Therapeutic Advances in Medical Oncology
- Published
- 2021
- Full Text
- View/download PDF
161. Clinico-metabolic characterization improves the prognostic value of histological growth patterns in patients undergoing surgery for colorectal liver metastases
- Author
-
Jean-Luc Van Laethem, V. Lucidi, Denis Larsimont, Ali Bohlok, Irina Vierasu, Serge Goldman, Pieter Demetter, Sophie Vankerckhove, Hugues Azema, Vincent Donckier, Alain Hendlisz, Patrick Flamen, Peter B. Vermeulen, Ivan Duran Derijckere, and Luc Dirix
- Subjects
Male ,Prognostic factor ,medicine.medical_specialty ,Disease free survival ,Resection ,03 medical and health sciences ,0302 clinical medicine ,Predictive Value of Tests ,Positron Emission Tomography Computed Tomography ,Overall survival ,medicine ,prognostic model ,Hepatectomy ,Humans ,In patient ,Colorectal ,Aged ,Retrospective Studies ,Fluorodeoxyglucose ,Framingham Risk Score ,medicine.diagnostic_test ,business.industry ,Liver Neoplasms ,General Medicine ,Middle Aged ,Prognosis ,Surgery ,Survival Rate ,liver metastasis ,Oncology ,Positron emission tomography ,030220 oncology & carcinogenesis ,Female ,030211 gastroenterology & hepatology ,Human medicine ,Colorectal Neoplasms ,business ,medicine.drug - Abstract
Background and Objectives The histological growth pattern (HGP) represents a strong prognostic factor in patients undergoing surgery for colorectal liver metastases (CRLM). We evaluated whether the combination of HGP with clinico-metabolic parameters could improve its prognostic value. Methods In a series of 108 patients undergoing resection of CRLM, the HGP of CRLM was scored according to international guidelines. Baseline clinico-metabolic clinical status was evaluated using a metabolic-Clinical Risk Score (mCRS), combining traditional Memorial Sloan Kettering-CRS parameters with the tumor-to-liver glucose uptake ratio as measured with (18)Fluorodeoxyglucose/positron emission tomography. Results In patients with desmoplastic HGP (DHGP) CRLM (20% of all patients), 5- and 10-years overall survival (OS) and disease free survival (DFS) were 66% and 43% and 37% and 24.5%, as compared with 35% and 21% and 11% and 11% in the non-DHGP group (p = 0.07 and 0.054). Among DHGP patients, those with a low-risk mCRS had improved postoperative outcomes, 5- and 10-years OS and DFS reaching 83.3% and 62.5% and 50% and 33%, as compared with 18% and 0% and 0% and 0% in high-risk mCRS patients (p = 0.007 and 0.003). In contrast, mCRS did not influence postoperative survivals in non-DHGP patients. Conclusions Combining the clinico-metabolic characteristics with the HGP may improve prognostication in patients undergoing surgery for CRLM.
- Published
- 2021
162. Rationale and design of REGINA, a phase II trial of neoadjuvant regorafenib, nivolumab, and short-course radiotherapy in stage II and III rectal cancer
- Author
-
Giacomo Bregni, Elena Trevisi, Chiara Senti, Gabriel Liberale, Lionel D'Hondt, Karen Geboes, Pashalina Kehagias, Caroline Vandeputte, Marc Buyse, Philippe Vergauwe, Yeter Gokburun, Francesco Sclafani, Jean-Luc Van Laethem, Marc Peeters, Maria Antonietta Bali, Camille Anastasia Chapot, Patrick Flamen, Alain Hendlisz, Javier Carrasco, Pieter Demetter, Marc Van den Eynde, Elena Acedo Reina, Andrea Pretta, Amélie Deleporte, Luigi Moretti, UCL - (MGD) Service d'oncologie médicale, and UCL - SSS/IREC/MONT - Pôle Mont Godinne
- Subjects
Oncology ,medicine.medical_specialty ,Colorectal cancer ,medicine.medical_treatment ,Stage ii ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Internal medicine ,Regorafenib ,medicine ,Radiology, Nuclear Medicine and imaging ,business.industry ,Standard treatment ,Généralités ,Hematology ,General Medicine ,medicine.disease ,Total mesorectal excision ,Radiation therapy ,chemistry ,030220 oncology & carcinogenesis ,Human medicine ,Nivolumab ,business ,Chemoradiotherapy - Abstract
SCOPUS: le.j, info:eu-repo/semantics/published
- Published
- 2021
163. Abstract CT192: Phase IIa open-label clinical study of intratumoural administration of BO-112 in combination with pembrolizumab in subjects with liver metastasis from colorectal cancer or gastric/gastro-oesophageal junction cancer
- Author
-
Mariano Ponz-Sarvise, Andrés Muñoz, Helena Escuin, Antonio Rampoldi, Vanesa Pons, Mercedes Rodríguez, Alain Hendlisz, Marya F. Chaney, Marc Van den Eynde, María Teresa Cano, Hans Prenen, Marisol Quintero, Elena Elez, Andrés Cervantes, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Service d'oncologie médicale, and UCL - (SLuc) Service d'hépato-gastro-entérologie
- Subjects
medicine.medical_specialty ,Tumor microenvironment ,Cancer Research ,Colorectal cancer ,business.industry ,Cancer ,Pembrolizumab ,medicine.disease ,Gastroenterology ,Metastasis ,Oncology ,Internal medicine ,medicine ,Biomarker (medicine) ,Immunogenic cell death ,business ,CD8 - Abstract
Protocol tittle: Study of BO-112 with pembrolizumab for colorectal or gastric/GEJ cancer with liver metastasis.Background: Gastric (GC), oesophagogastric junction (EGJC) and colorectal tumors (CRC) with microsatellite stability (MSS) are poorly responders to PD(L)-1 inhibition, due to low CD8+ T cell infiltration and PD-L1 expression. Therefore, modulation of the tumor microenvironment (TME) could increase disease control. In these tumors the presence of liver lesions is difficult to control because of the hepatic immune tolerance. Control of the hepatic disease could increase survival.BO-112 is a non-coding dsRNA agonist of TLR3, MDA5 and RIG-I which activates the innate and adaptative immune response, inducing apoptosis and immunogenic cell death, with a local and a systemic effect. A prior Phase I trial showed that the combination of pembrolizumab and intratumoral (IT) BO-112 has a good safety profile and encouraging activity. Study design: This is a single arm phase IIa trial to assess the efficacy of intrahepatic IT BO-112 and iv pembrolizumab in 3W cycles in patients with MSS CRC, GC or EGJ tumors. Up to 69 patients with at least one liver lesion and 2 prior lines for CRC and 1 for GC/EGJC will be enrolled. Primary endpoints: ORR and related TEAEs ≥ grade 3. Secondary endpoints: ORR (iRECIST), PFS, 6-months OS and safety. Exploratory endpoint: Changes in TME (PD-L1 expression and CD8+ T cell infiltration) from baseline to C2D1.Results: A total of 11 CRC and 7 GC/EGJC patients were enrolled since July 2020. This abstract focuses on the CRC patients´ biomarker expression. These patients had low PD-L1 CPS (combined positive score) expression and CD8+ T cell infiltration with a median value of 5 and 4%, respectively, in the TME at baseline. Following two IT BO-112 injections, an important increase in PD-L1 expression and CD8+ T cell infiltration was observed in 5 and 7 patients, respectively. PD-L1 CPS median value increased to 37.9 while CD8+ T cell infiltration median values raised to 12.9%.Conclusions: A meaningful increase in PD-L1 expression and CD8+ T cell infiltration was achieved in MSS CRC patients after one cycle of BO-112-pembrolizumab. Table 1.Baseline characteristics and TME changesBaseline characteristicsCRC N=11Demographics-Sex-Male-Female-Age (mean, range)7 (63.6%)4 (36.4%)55 (38-74)Location of primary tumor-Right colon-Left colon2 (36.4%)7 (63.6%)Presence of extrahepatic disease-No-YesLocation of the extrahepatic disease-Lungs-Lymph nodes-Ohers (bone, adrenal gland, peritoneum, pancreas)2 (18.2%)9 (81.8%)6 (54.5%)5 (45.5%)1 (9.1%)Molecular characteristics:-MMR status-MSS-KRAS-Wild type-Mutant -PD-L1-CPS Citation Format: Mariano Ponz-Sarvisé, Elena Élez, Andrés Muñoz, Marc Van den Eynde, Antonio Gaetano Rampoldi, Alain Hendlisz, Hans Prenen, Mercedes Rodríguez, María Teresa Cano, Marya Chaney, Helena Escuin, Vanesa Pons, Marisol Quintero, Andrés Cervantes. Phase IIa open-label clinical study of intratumoural administration of BO-112 in combination with pembrolizumab in subjects with liver metastasis from colorectal cancer or gastric/gastro-oesophageal junction cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr CT192.
- Published
- 2021
164. Rationale and design of REGINA, a phase II trial of neoadjuvant regorafenib, nivolumab, and short-course radiotherapy in stage II and III rectal cancer
- Author
-
UCL - (MGD) Service d'oncologie médicale, UCL - SSS/IREC/MONT - Pôle Mont Godinne, Bregni, Giacomo, Vandeputte, Caroline, Pretta, Andrea, Senti, Chiara, Trevisi, Elena, Acedo Reina, Elena, Kehagias, Pashalina, Liberale, Gabriel, Moretti, Luigi, Bali, Maria Antonietta, Demetter, Pieter, Flamen, Patrick, Carrasco, Javier, D'Hondt, Lionel, Geboes, Karen, Gokburun, Yeter, Peeters, Marc, Van den Eynde, Marc, Van Laethem, Jean-Luc, Vergauwe, Philippe, Chapot, Camille Anastasia, Buyse, Marc, Deleporte, Amelie, Hendlisz, Alain, Sclafani, Francesco, UCL - (MGD) Service d'oncologie médicale, UCL - SSS/IREC/MONT - Pôle Mont Godinne, Bregni, Giacomo, Vandeputte, Caroline, Pretta, Andrea, Senti, Chiara, Trevisi, Elena, Acedo Reina, Elena, Kehagias, Pashalina, Liberale, Gabriel, Moretti, Luigi, Bali, Maria Antonietta, Demetter, Pieter, Flamen, Patrick, Carrasco, Javier, D'Hondt, Lionel, Geboes, Karen, Gokburun, Yeter, Peeters, Marc, Van den Eynde, Marc, Van Laethem, Jean-Luc, Vergauwe, Philippe, Chapot, Camille Anastasia, Buyse, Marc, Deleporte, Amelie, Hendlisz, Alain, and Sclafani, Francesco
- Published
- 2021
165. The absence of benefit of perioperative chemotherapy in initially resectable peritoneal metastases of colorectal cancer origin treated with complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A retrospective analysis.
- Author
-
UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Service de chirurgie et transplantation abdominale, UCL - (SLuc) Unité d'oncologie médicale, Repullo, Deborah J, Barbois, Sandrine, Léonard, Daniel, Bohlok, Ali, Van den Audenaeren, Estelle T, Hendlisz, Alain, Van den Eynde, Marc, Donckier, Vincent, Kartheuser, Alex, Liberale, Gabriel, UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Service de chirurgie et transplantation abdominale, UCL - (SLuc) Unité d'oncologie médicale, Repullo, Deborah J, Barbois, Sandrine, Léonard, Daniel, Bohlok, Ali, Van den Audenaeren, Estelle T, Hendlisz, Alain, Van den Eynde, Marc, Donckier, Vincent, Kartheuser, Alex, and Liberale, Gabriel
- Abstract
The aim of this study was to compare the outcome of patients with peritoneal metastasis (PM) of colorectal origin treated with complete cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) with or without perioperative systemic chemotherapy (PCT+/PCT-). Retrospective analysis of 125 patients treated with complete CRS (R0/R1) and HIPEC for PM from colorectal origin in two Belgian academic centers between 2008 and 2017. Disease-free survival (DFS) and overall survival (OS) were assessed with regard to PCT. Statistical analyses were adjusted for non-balanced survival risk factors. The PCT+ group (n = 67) received at least 5 cycles of PCT and the PCT-group (n = 56) did not receive PCT. The groups were well balanced for all prognostic factors except presentation of synchronous disease (more in PCT+). Survival analysis was adjusted to peritoneal cancer index and presentation of synchronous disease. After a median follow-up of 54±5-months, the 1, 3, 5-years OS in the PCT+ group were 98%, 59% and 35% compared to 97%, 77% and 56% in the PCT-group (HR = 1.46; 95% CI:0.87-2.47; p = 0.155). The 1,3 and 5 years DFS in the PCT+ group were 47%, 13% and 6% compared to 58%, 29% and 26% respectively in the PCT- (HR = 1.22; 95% CI:0.78-1.92; p = 0.376). This study does not show any clear benefit of PCT in carefully selected patients undergoing R0/R1 CRS and HIPEC for colorectal PM. The ongoing CAIRO6 trial randomizing CRS/HIPEC versus CRS/HIPEC and PCT will probably clarify the role of PCT in patients with resectable PM.
- Published
- 2021
166. Fortnightly or fractionated weekly docetaxel-cisplatin-5-FU as first-line treatment in advanced gastric and gastroesophageal junction adenocarcinoma: The randomized phase II DoGE study.
- Author
-
UCL - (MGD) Service d'hématologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, Deleporte, Amélie, Van den Eynde, Marc, Forget, Frédéric, Holbrechts, Stéphane, Delaunoit, Thierry, Houbiers, Ghislain, Kalantari, Hassan R, Laurent, Stéphanie, Vanderstraeten, Erik, De Man, Marc, Vergauwe, Philippe, Clausse, Marylene, Van Der Auwera, Jacques, D'Hondt, Lionel, Pierre, Pascal, Ghillemijn, Bjorn, Covas, Angelique, Paesmans, Marianne, Ameye, Lieveke, Awada, Ahmad, Sclafani, Francesco, Hendlisz, Alain, UCL - (MGD) Service d'hématologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, Deleporte, Amélie, Van den Eynde, Marc, Forget, Frédéric, Holbrechts, Stéphane, Delaunoit, Thierry, Houbiers, Ghislain, Kalantari, Hassan R, Laurent, Stéphanie, Vanderstraeten, Erik, De Man, Marc, Vergauwe, Philippe, Clausse, Marylene, Van Der Auwera, Jacques, D'Hondt, Lionel, Pierre, Pascal, Ghillemijn, Bjorn, Covas, Angelique, Paesmans, Marianne, Ameye, Lieveke, Awada, Ahmad, Sclafani, Francesco, and Hendlisz, Alain
- Abstract
While docetaxel/cisplatin/5-fluorouracil (DCF) outperforms CF in first-line gastric adenocarcinoma, toxicity remains an issue. This multicenter phase II trial randomized chemonaïve metastatic gastric adenocarcinoma patients to fractionated weekly DCF (D 40 mg/m , C 35 mg/m², F 1800 mg/m² over 24 h, on days 1 and 8 every 3 weeks, arm (1) or fortnightly DCF (D 50 mg/m , C 50 mg/m², F 2000 mg/m² over 48 h every 2 weeks, arm (2). Prophylactic granulocyte colony-stimulating factor (G-CSF) was not allowed. The primary endpoint was the rate of febrile neutropenia within the first six treatment weeks (early FN). A total of 106 eligible patients were recruited. The early and overall FN rates were 9.5% and 17% in arm 1, respectively, and 5.9% and 8% in arm 2, respectively. Grade ≥3 toxicities occurred in 81% of patients in arm 1 and 90% of patients in arm 2, the most common being neutropenia (33% vs. 61%), fatigue (27% vs. 25%), vomiting (21% vs. 12%), anorexia (19% vs. 18%), and diarrhea (17% vs. 10%). Median progression-free survival and overall survival were 5.1 (95% CI, 3.2-6.5) and 8.2 months (95% CI, 6.0-14.5), respectively, in arm 1 and 5.2 (95% CI, 3.0-6.9) and 11.9 months (95% CI, 7.4-15.9), respectively, in arm 2. Fractionated weekly and fortnightly DCF regimens are associated with a low risk of early FN, and a better hematological toxicity profile as compared to historical DCF without compromising efficacy. Both regimens offer greater convenience removing the need for systematic use of prophylactic G-CSF.
- Published
- 2021
167. Sex and Regorafenib Toxicity in Refractory Colorectal Cancer: Safety Analysis of the RegARd-C Trial.
- Author
-
UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'oncologie médicale, Vandeputte, Caroline, Bregni, Giacomo, Gkolfakis, Paraskevas, Guiot, Thomas, Pretta, Andrea, Kehagias, Pashalina, Senti, Chiara, Reina, Elena Acedo, Van Bogaert, Camille, Deleporte, Amélie, Geboes, Karen, Delaunoit, Thierry, Demolin, Gauthier, Peeters, Marc, D'Hondt, Lionel, Janssens, Jos, Carrasco, Javier, Holbrechts, Stephane, Goeminne, Jean-Charles, Vergauwe, Philippe, Van Laethem, Jean-Luc, Flamen, Patrick, Hendlisz, Alain, Sclafani, Francesco, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'oncologie médicale, Vandeputte, Caroline, Bregni, Giacomo, Gkolfakis, Paraskevas, Guiot, Thomas, Pretta, Andrea, Kehagias, Pashalina, Senti, Chiara, Reina, Elena Acedo, Van Bogaert, Camille, Deleporte, Amélie, Geboes, Karen, Delaunoit, Thierry, Demolin, Gauthier, Peeters, Marc, D'Hondt, Lionel, Janssens, Jos, Carrasco, Javier, Holbrechts, Stephane, Goeminne, Jean-Charles, Vergauwe, Philippe, Van Laethem, Jean-Luc, Flamen, Patrick, Hendlisz, Alain, and Sclafani, Francesco
- Abstract
Regorafenib is a standard treatment for refractory metastatic colorectal cancer (mCRC). In view of the toxicity burden, significant research efforts have been made to increase the therapeutic ratio of this multikinase inhibitor. Predictive factors for treatment-related adverse events (TRAEs), however, are still lacking. We assessed the association between a number of baseline clinical, laboratory and imaging parameters and the occurrence of TRAEs in 136 patients who had received regorafenib (160 mg/day, 3-weeks-on/1-week-off) in a prospective phase II clinical trial. Grade ≥ 2 TRAEs during the first cycle of treatment (84% vs. 60%, P = .002) and grade ≥ 3 TRAEs throughout the whole treatment (71% vs. 53%, P = .035) occurred more frequently in females, with sex being the only independent predictive factor of early and any-time toxicity (OR 3.4; 95% CI: 1.2-11.1, P = .02 and OR 2.1; 95% CI: 1.0-4.4, P = .045, respectively). Fatigue, anorexia, hypertension, and rash were reported significantly more frequently by females than males (P < .04). Females were also more likely to suffer early (19% vs. 5%, P = .014) and any-time serious AEs (28% vs. 9%, P = .005), and to require early dose modifications (55% vs. 37%, P = .055). This is the first study showing an association between sex and TRAEs during regorafenib treatment for mCRC. If confirmed in larger, independent series, these results could pave the way for the implementation of personalized regorafenib dosing strategies with the potential to optimize oncological outcomes while reducing toxicity and preserving quality of life.
- Published
- 2021
168. Abstract CT192: Phase IIa open-label clinical study of intratumoural administration of BO-112 in combination with pembrolizumab in subjects with liver metastasis from colorectal cancer or gastric/gastro-oesophageal junction cancer
- Author
-
UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Service d'oncologie médicale, UCL - (SLuc) Service d'hépato-gastro-entérologie, Ponz-Sarvisé, Mariano, Élez, Elena, Muñoz, Andrés, Van den Eynde, Marc, Rampoldi, Antonio Gaetano, Hendlisz, Alain, Prenen, Hans, Rodríguez, Mercedes, Cano, María Teresa, Chaney, Marya, Escuin, Helena, Pons, Vanesa, Quintero, Marisol, Cervantes, Andrés, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Service d'oncologie médicale, UCL - (SLuc) Service d'hépato-gastro-entérologie, Ponz-Sarvisé, Mariano, Élez, Elena, Muñoz, Andrés, Van den Eynde, Marc, Rampoldi, Antonio Gaetano, Hendlisz, Alain, Prenen, Hans, Rodríguez, Mercedes, Cano, María Teresa, Chaney, Marya, Escuin, Helena, Pons, Vanesa, Quintero, Marisol, and Cervantes, Andrés
- Abstract
Protocol tittle: Study of BO-112 with pembrolizumab for colorectal or gastric/GEJ cancer with liver metastasis.Background: Gastric (GC), oesophagogastric junction (EGJC) and colorectal tumors (CRC) with microsatellite stability (MSS) are poorly responders to PD(L)-1 inhibition, due to low CD8+ T cell infiltration and PD-L1 expression. Therefore, modulation of the tumor microenvironment (TME) could increase disease control. In these tumors the presence of liver lesions is difficult to control because of the hepatic immune tolerance. Control of the hepatic disease could increase survival.BO-112 is a non-coding dsRNA agonist of TLR3, MDA5 and RIG-I which activates the innate and adaptative immune response, inducing apoptosis and immunogenic cell death, with a local and a systemic effect. A prior Phase I trial showed that the combination of pembrolizumab and intratumoral (IT) BO-112 has a good safety profile and encouraging activity. Study design: This is a single arm phase IIa trial to assess the efficacy of intrahepatic IT BO-112 and iv pembrolizumab in 3W cycles in patients with MSS CRC, GC or EGJ tumors. Up to 69 patients with at least one liver lesion and 2 prior lines for CRC and 1 for GC/EGJC will be enrolled. Primary endpoints: ORR and related TEAEs ≥ grade 3. Secondary endpoints: ORR (iRECIST), PFS, 6-months OS and safety. Exploratory endpoint: Changes in TME (PD-L1 expression and CD8+ T cell infiltration) from baseline to C2D1.Results: A total of 11 CRC and 7 GC/EGJC patients were enrolled since July 2020. This abstract focuses on the CRC patients´ biomarker expression. These patients had low PD-L1 CPS (combined positive score) expression and CD8+ T cell infiltration with a median value of 5 and 4%, respectively, in the TME at baseline. Following two IT BO-112 injections, an important increase in PD-L1 expression and CD8+ T cell infiltration was observed in 5 and 7 patients, respectively. PD-L1 CPS median value increased to 37.9 while CD8+ T cell infiltration
- Published
- 2021
169. Clinico-metabolic characterization improves the prognostic value of histological growth patterns in patients undergoing surgery for colorectal liver metastases.
- Author
-
Bohlok, Ali, Duran Derijckere, Ivan, Azema, Hugues, Lucidi, Valerio, Vankerckhove, Sophie, Hendlisz, Alain, Van Laethem, Jean-Luc, Vierasu, Irina, Goldman, Serge, Flamen, Patrick, Larsimont, Denis, Demetter, Pieter, Dirix, Luc Y, Vermeulen, Peter B., Donckier De Donceel, Vincent, Bohlok, Ali, Duran Derijckere, Ivan, Azema, Hugues, Lucidi, Valerio, Vankerckhove, Sophie, Hendlisz, Alain, Van Laethem, Jean-Luc, Vierasu, Irina, Goldman, Serge, Flamen, Patrick, Larsimont, Denis, Demetter, Pieter, Dirix, Luc Y, Vermeulen, Peter B., and Donckier De Donceel, Vincent
- Abstract
The histological growth pattern (HGP) represents a strong prognostic factor in patients undergoing surgery for colorectal liver metastases (CRLM). We evaluated whether the combination of HGP with clinico-metabolic parameters could improve its prognostic value., SCOPUS: ar.j, info:eu-repo/semantics/published
- Published
- 2021
170. Plasticity of esophageal progenitors
- Author
-
Beck, Benjamin, Moreno, Christophe, Garcia, Marie-Isabelle, Hendlisz, Alain, Stamatopoulos, Basile, Sanchez Danes, Adriana, Gillet, Jean-Pierre, Vercauteren Drubbel, Alizée, Beck, Benjamin, Moreno, Christophe, Garcia, Marie-Isabelle, Hendlisz, Alain, Stamatopoulos, Basile, Sanchez Danes, Adriana, Gillet, Jean-Pierre, and Vercauteren Drubbel, Alizée
- Abstract
Une métaplasie se définit comme le remplacement d’un type cellulaire par un autre dans le même tissu. Les métaplasies cylindriques de l’œsophage sont caractérisées par le remplacement de l’épithélium squameux de l’œsophage par un épithélium cylindrique ressemblant à celui de l’estomac et/ou de l’intestin. La cellule à l’origine de ces métaplasies est cependant encore sujette à débat. Jusqu’à présent, des études ont montré que ces métaplasies seraient plutôt la conséquence d’une compétition entre l’épithélium cylindrique et l’épithélium squameux. Or, une étude récente a montré que la transdifférenciation de certains kératinocytes pouvait conduire à la formation de métaplasies in vivo, mais que les cellules de l’œsophage en étaient incapables. Ceci soulève donc la question de la plasticité des cellules de l’œsophage in vivo et de leur capacité à changer leur programme de différenciation.Afin d’étudier la plasticité des cellules de l’œsophage, nous avons combiné la transcriptomique, le suivi de cellules in situ et le séquençage d’ARN à l’échelle unicellulaire dans différents modèles de souris transgéniques. Nous avons démontré que le développement des métaplasies de l’œsophage est associé à la réactivation de la voie de signalisation Hedgehog dans les cellules épithéliales squameuses. Nous avons ensuite démontré que la réactivation de cette voie dans les cellules de l’œsophage induit une dédifférenciation associée à la réactivation d’un programme transcriptionnel et épigénétique similaire à celui de l’œsophage embryonnaire. De plus, une partie de ces cellules dédifférenciées sont capables d’activer un nouveau programme de différenciation menant à l’expression de marqueurs intestinaux. L’activation de ce nouveau programme dépend de l’expression du facteur de transcription Sox9. Notre travail a donc démontré que les kératinocytes de l’œsophage peuvent réaliser une conversion squamo-cylindrique complète in vivo et, ainsi, potentiellement participer à la formation de métap, Doctorat en Sciences biomédicales et pharmaceutiques (Médecine), info:eu-repo/semantics/nonPublished
- Published
- 2021
171. Age of Less than Forty Years Seems Not Be an Independent Factor for Poor Prognosis in Patients Undergoing Surgery for CRC
- Author
-
Wagner, Cathy, Jacobs, Nathan, Moreau, Michel, Bouazza, Fikri, Bohlok, Ali, Deleporte, Amélie, Sclafani, Francesco, Hendlisz, Alain, Donckier De Donceel, Vincent, Liberale, Gabriel, Wagner, Cathy, Jacobs, Nathan, Moreau, Michel, Bouazza, Fikri, Bohlok, Ali, Deleporte, Amélie, Sclafani, Francesco, Hendlisz, Alain, Donckier De Donceel, Vincent, and Liberale, Gabriel
- Abstract
info:eu-repo/semantics/published
- Published
- 2021
172. Total neoadjuvant therapy for rectal cancer: Making sense of the results from the RAPIDO and PRODIGE 23 trials
- Author
-
Giunta, Emilio Francesco, Bregni, Giacomo, Pretta, Andrea, Deleporte, Amélie, Liberale, Gabriel, Bali, A.M., Moretti, Luigi, Troiani, Teresa, Ciardiello, Fortunato, Hendlisz, Alain, Sclafani, Francesco, Giunta, Emilio Francesco, Bregni, Giacomo, Pretta, Andrea, Deleporte, Amélie, Liberale, Gabriel, Bali, A.M., Moretti, Luigi, Troiani, Teresa, Ciardiello, Fortunato, Hendlisz, Alain, and Sclafani, Francesco
- Abstract
A few months ago, results from two randomised phase III trials of total neoadjuvant therapy (TNT) in locally advanced rectal cancer were presented (RAPIDO and PRODIGE 23), consistently showing better short- and long-term outcomes with TNT as compared with standard neoadjuvant long-course chemoradiotherapy (CRT) or short-course radiotherapy (SCRT). These results represent corroborating evidence in support of a practice that many centres had already implemented based on promising preliminary data. Also, they provide new, high-level evidence to endorse TNT as a new management option in the treatment algorithm of stage II-III rectal cancer in those centres where CRT and SCRT have long remained the only accepted standard neoadjuvant treatments. Having two consistently positive trials is certainly reassuring regarding the potential of TNT as a general treatment approach. Nevertheless, substantial differences between these trials pose important challenges in relation to the generalisability and applicability of their results, and translation of the same into practical clinical recommendations. In this article, we address a number of key questions that the RAPIDO and PRODIGE 23 trials have raised among the broad community of gastrointestinal oncologists, proposing an interpretation of the data that may help the decision making, and highlighting grey areas that warrant further investigation., SCOPUS: re.j, info:eu-repo/semantics/published
- Published
- 2021
173. Buschke-löwenstein tumor in a human immunodeficiency virus-positive patient: A case report and short literature review
- Author
-
Ledouble, Vinciane, Sclafani, Francesco, Hendlisz, Alain, Gomez-Galdon, Maria, Liberale, Gabriel, Ledouble, Vinciane, Sclafani, Francesco, Hendlisz, Alain, Gomez-Galdon, Maria, and Liberale, Gabriel
- Abstract
Giant condyloma acuminatum, also known as Buschke-Löwen-stein tumor, is a rare variant of verrucous carcinoma presenting in the ano-genital region. While its metastatic potential is limited, aggressive local growth is common, with invasion and destruction of the surrounding tissues often causing important therapeutic challenges. Also, data to inform the optimal management approach are scarce and mostly limited to anectodical reports. We present the case of a human immunodeficiency virus-associated locally advanced Buschke Löwenstein tumor that was successfully treated with extensive surgery., SCOPUS: re.j, info:eu-repo/semantics/published
- Published
- 2021
174. Rationale and design of REGINA, a phase II trial of neoadjuvant regorafenib, nivolumab, and short-course radiotherapy in stage II and III rectal cancer
- Author
-
Bregni, Giacomo, Vandeputte, Caroline, Pretta, Andrea, Senti, Chiara, Trevisi, Elena, Acedo Reina, Elena, Kehagias, Pashalina, Liberale, Gabriel, Moretti, Luigi, Bali, Maria Antonietta, Demetter, Pieter, Flamen, Patrick, Carrasco, J., D'Hondt, Lionel, Geboes, K., Gokburun, Yeter, Peeters, Michel, Van Den Eynde, Marc, Van Laethem, Jean-Luc, Vergauwe, Philippe, Chapot, Camille Anastasia, Buyse, Marc, Deleporte, Amélie, Hendlisz, Alain, Sclafani, Francesco, Bregni, Giacomo, Vandeputte, Caroline, Pretta, Andrea, Senti, Chiara, Trevisi, Elena, Acedo Reina, Elena, Kehagias, Pashalina, Liberale, Gabriel, Moretti, Luigi, Bali, Maria Antonietta, Demetter, Pieter, Flamen, Patrick, Carrasco, J., D'Hondt, Lionel, Geboes, K., Gokburun, Yeter, Peeters, Michel, Van Den Eynde, Marc, Van Laethem, Jean-Luc, Vergauwe, Philippe, Chapot, Camille Anastasia, Buyse, Marc, Deleporte, Amélie, Hendlisz, Alain, and Sclafani, Francesco
- Abstract
SCOPUS: le.j, info:eu-repo/semantics/published
- Published
- 2021
175. The absence of benefit of perioperative chemotherapy in initially resectable peritoneal metastases of colorectal cancer origin treated with complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A retrospective analysis
- Author
-
Repullo, Deborah, Barbois, Sandrine, Leonard, Daniel, Bohlok, Ali, Van den Audenaeren, Estelle E.T., Hendlisz, Alain, Van Den Eynde, Marc, Donckier De Donceel, Vincent, Kartheuser, Alex, Liberale, Gabriel, Repullo, Deborah, Barbois, Sandrine, Leonard, Daniel, Bohlok, Ali, Van den Audenaeren, Estelle E.T., Hendlisz, Alain, Van Den Eynde, Marc, Donckier De Donceel, Vincent, Kartheuser, Alex, and Liberale, Gabriel
- Abstract
Introduction: The aim of this study was to compare the outcome of patients with peritoneal metastasis (PM) of colorectal origin treated with complete cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) with or without perioperative systemic chemotherapy (PCT+/PCT-). Patients and methods: Retrospective analysis of 125 patients treated with complete CRS (R0/R1) and HIPEC for PM from colorectal origin in two Belgian academic centers between 2008 and 2017. Disease-free survival (DFS) and overall survival (OS) were assessed with regard to PCT. Statistical analyses were adjusted for non-balanced survival risk factors. Results: The PCT+ group (n = 67) received at least 5 cycles of PCT and the PCT-group (n = 56) did not receive PCT. The groups were well balanced for all prognostic factors except presentation of synchronous disease (more in PCT+). Survival analysis was adjusted to peritoneal cancer index and presentation of synchronous disease. After a median follow-up of 54±5-months, the 1, 3, 5-years OS in the PCT+ group were 98%, 59% and 35% compared to 97%, 77% and 56% in the PCT-group (HR = 1.46; 95% CI:0.87–2.47; p = 0.155). The 1,3 and 5 years DFS in the PCT+ group were 47%, 13% and 6% compared to 58%, 29% and 26% respectively in the PCT- (HR = 1.22; 95% CI:0.78–1.92; p = 0.376). Conclusion: This study does not show any clear benefit of PCT in carefully selected patients undergoing R0/R1 CRS and HIPEC for colorectal PM. The ongoing CAIRO6 trial randomizing CRS/HIPEC versus CRS/HIPEC and PCT will probably clarify the role of PCT in patients with resectable PM., SCOPUS: ar.j, info:eu-repo/semantics/published
- Published
- 2021
176. Lesion-based detection of early chemosensitivity using serial static FDG PET/CT in metastatic colorectal cancer
- Author
-
Buvat, Irène, Necib, Hatem, Garcia, Camilo, Wagner, Antoine, Vanderlinden, Bruno, Emonts, Patrick, Hendlisz, Alain, and Flamen, Patrick
- Published
- 2012
- Full Text
- View/download PDF
177. 599P R-IMMUNE: A phase Ib/II study to evaluate safety and efficacy of atezolizumab combined with radio-chemotherapy in a preoperative setting for patients with locally advanced rectal cancer (LARC)
- Author
-
Carrasco, J., Beniuga, G., Jouret-Mourin, A., Baldin, P., Sinapi, I., Schroeder, D., De Cuyper, A., Sclafani, F., Hendlisz, A., van Laethem, J-L., Boulanger, A-S., Van Ooteghem, G., Dermine, A., Delmarcelle, S., Huyghe, N., Bar, I., and van den Eynde, M.
- Published
- 2023
- Full Text
- View/download PDF
178. Association between the histopathological growth patterns of liver metastases and survival after hepatic surgery in breast cancer patients
- Author
-
Maxim De Schepper, Denis Larsimont, Steven Van Laere, Valerio Lucidi, Christine Desmedt, Philippe Aftimos, Michail Ignatiadis, Elia Biganzoli, Luc Dirix, Alain Hendlisz, Martine Piccart, Vincent Donckier, Peter B. Vermeulen, Ali Bohlok, Francois Richard, Jean Christophe Noël, Tatjana Geukens, Sophia Leduc, Christos Sotiriou, Lara Botzenhart, and Emily Latacz
- Subjects
0301 basic medicine ,Pathology ,medicine.medical_specialty ,Fibrous tissue ,Brief Communication ,03 medical and health sciences ,Prognostic markers ,0302 clinical medicine ,Breast cancer ,Overall survival ,Medicine ,Pharmacology (medical) ,Radiology, Nuclear Medicine and imaging ,RC254-282 ,Science & Technology ,business.industry ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Généralités ,medicine.disease ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,Hepatic surgery ,Cancer cell ,Human medicine ,business ,Life Sciences & Biomedicine ,Liver parenchyma - Abstract
Currently, there are no markers to identify patients with liver-only or liver-dominant metastases that would benefit from hepatic surgery. Here we characterized histopathological growth patterns (HGPs) of liver metastases in a consecutive series of 36 breast cancer patients who underwent hepatic surgery. Survival analyses showed that the presence of a desmoplastic HGP in the liver metastases (a rim of fibrous tissue separating cancer cells from the liver parenchyma, present in 20 (56%) patients) is independently associated with favorable progression-free and overall survival when compared with the replacement HGP (cancer cells growing into the liver parenchyma, present in 16 (44%) patients)., SCOPUS: ar.j, info:eu-repo/semantics/published
- Published
- 2020
179. Postoperative C-reactive protein kinetics predict postoperative complications in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis
- Author
-
Gabriel Liberale, Amélie Deleporte, Antoine El Asmar, Maher Khalife, Melissa Bendavides, Vincent Donckier, Alain Hendlisz, and Michel Moreau
- Subjects
medicine.medical_specialty ,lcsh:Surgery ,Hyperthermic Intraperitoneal Chemotherapy ,Gastroenterology ,lcsh:RC254-282 ,C-reactive protein ,03 medical and health sciences ,Postoperative complications ,0302 clinical medicine ,Surgical oncology ,Internal medicine ,medicine ,Humans ,Platelet ,In patient ,Chirurgie ,Peritoneal Neoplasms ,Retrospective Studies ,biology ,HIPEC ,business.industry ,Research ,Retrospective cohort study ,lcsh:RD1-811 ,Cytoreduction Surgical Procedures ,Hyperthermia, Induced ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Prognosis ,Combined Modality Therapy ,Peritoneal carcinomatosis ,Cancérologie ,Kinetics ,Oncology ,030220 oncology & carcinogenesis ,Chemotherapy, Cancer, Regional Perfusion ,biology.protein ,030211 gastroenterology & hepatology ,Surgery ,Hyperthermic intraperitoneal chemotherapy ,Cytoreductive surgery ,business ,Prediction - Abstract
Background: Relatively high morbidity rates are reported after cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). However, early predictors of complications after CRS plus HIPEC have not been identified. The aim of this study was to evaluate the predictive role of early postoperative serum C-reactive protein (CRP) level (Day 2–4) for the detection of post-operative complications. Patients and methods: We performed a retrospective study including 94 patients treated with complete CRS (R1) and HIPEC for PC from various primary origins (2011–2016). Post-operative complications were recorded. The values for postoperative inflammatory markers (white blood cells [WBC] and platelet counts, CRP) were compared between the different groups. Results: CRP on post-operative days 2–4 was significantly higher in patients with than without complications (124 mg/L vs 46 mg/L; p < 0.0001) and higher in those with more major complications (162 mg/L vs 80 mg/L; p < 0.0012). WBC and platelet counts showed no difference within 5 days postoperatively. Conclusion: CRP levels, and kinetics mainly, between post-operative day 2 and 4, are decisive predictive markers of early and late post-operative complications after CRS plus HIPEC. The presence of post-operative complications should be suspected in patients with a high CRP mean, and a plateau level (days 2–4)., SCOPUS: ar.j, info:eu-repo/semantics/published
- Published
- 2020
180. PD-0420: Induction by mFOLFIRINOX followed by SIB-SBRT for the neoadjuvant treatment of pancreatic cancer
- Author
-
Laura Mans, Jean-Luc Engelholm, Yeter Gokburun, Patrizia Loi, Luigi Moretti, J. Van Laethem, Pierre Eisendrath, Maria Antonietta Bali, Julie Navez, A. Hendlisz, T. De Grez, D. Van Gestel, Jean Closset, and Christelle Bouchart
- Subjects
Oncology ,Cancérologie ,medicine.medical_specialty ,business.industry ,Neoadjuvant treatment ,Internal medicine ,Pancreatic cancer ,Medicine ,Radiology, Nuclear Medicine and imaging ,Hematology ,business ,medicine.disease - Abstract
info:eu-repo/semantics/published
- Published
- 2020
181. Infiltrative tumour growth pattern correlates with poor outcome in oesophageal cancer
- Author
-
Alain Hendlisz, Pieter Demetter, Caroline Vandeputte, Tom Lenaerts, Ligia Craciun, Maelle Anciaux, Sylvie Vande Velde, Roland De Wind, Amélie Deleporte, Denis Larsimont, Amélie Deleruelle, Francesco Sclafani, Gaspard Lens, Vincent Donckier, Maria Gomez Galdon, Informatics and Applied Informatics, and Artificial Intelligence
- Subjects
0301 basic medicine ,Oncology ,Male ,Esophageal Neoplasms ,Angiogenesis ,Cohort Studies ,0302 clinical medicine ,Belgium ,Gene expression ,molecular biology ,Data Management ,Neovascularization, Pathologic ,Gastroenterology ,Sciences bio-médicales et agricoles ,Middle Aged ,Prognosis ,Up-Regulation ,Gene Expression Regulation, Neoplastic ,Real-time polymerase chain reaction ,030220 oncology & carcinogenesis ,Cohort ,Carcinoma, Squamous Cell ,histopathology ,Oesophageal Cancer ,Female ,oesophageal cancer ,medicine.medical_specialty ,Epithelial-Mesenchymal Transition ,Adenocarcinoma ,Real-Time Polymerase Chain Reaction ,03 medical and health sciences ,Internal medicine ,medicine ,Humans ,In patient ,Neoplasm Invasiveness ,lcsh:RC799-869 ,Survival rate ,Gene ,Aged ,Cell Proliferation ,Retrospective Studies ,Inflammation ,business.industry ,Sequence Analysis, RNA ,030104 developmental biology ,Histopathology ,lcsh:Diseases of the digestive system. Gastroenterology ,business - Abstract
Oesophageal cancer (OEC) is an aggressive disease with a poor survival rate. Prognostic markers are thus urgently needed. Due to the demonstrated prognostic value of histopathological growth pattern (HGP) in other cancers, we performed a retrospective assessment of HGP in patients suffering from invasive OEC., info:eu-repo/semantics/published
- Published
- 2020
182. Evaluation of the incidence of deep epigastric and cardiophrenic angle lymph nodes involvement, in patients with recurrent disease after cytoreductive surgery, for colorectal cancer
- Author
-
Antoine El Asmar, Michael Vouche, Maria Gomez Galdon, Denis Larsimont, Francesco Sclafani, Alain Hendlisz, Vincent Donckier, and Gabriel Liberale
- Subjects
Oncology ,Surgery ,General Medicine - Published
- 2022
183. Non-desmoplastic histological growth pattern predicts the risk of microscopically invaded margin and postoperative survival in patients undergoing resection of colorectal liver metastases
- Author
-
Lisa Inchiostro, Ali Bohlok, Valerio Lucidi, Pieter Demetter, Sophie Vankerckhove, Alain Hendlisz, Jean Luc Van Laethem, Denis Larsimont, Peter Vermeulen, and Vincent Donckier
- Subjects
Oncology ,Surgery ,General Medicine - Published
- 2022
184. Determination of the histological growth pattern of colorectal peritoneal metastases and evaluation of their prognostic impact
- Author
-
Antoine El Asmar, Fahd Fares, Pieter Demetter, Francesco Sclafani, Alain Hendlisz, Denis Larsimont, Vincent Donckier, Peter Vermeulen, and Gabriel Liberale
- Subjects
Oncology ,Surgery ,General Medicine - Published
- 2022
185. REGINA: A phase II trial of neoadjuvant regorafenib (Rego) in combination with nivolumab (Nivo) and short-course radiotherapy (SCRT) in intermediate-risk, stage II-III rectal cancer (RC)
- Author
-
Giacomo Bregni, Chiara Senti, Elena Acedo Reina, Paraskevas Gkolfakis, Luigi Moretti, Ana Veron, Pieter Demetter, Gabriel Liberale, Javier Carrasco, Karen Paula Geboes, Yeter Gokburun, Marc Peeters, Marc Van Den Eynde, Jean-Luc Van Laethem, Philippe Vergauwe, Marc E. Buyse, Amélie Deleporte, Alain Hendlisz, and Francesco Sclafani
- Subjects
Cancer Research ,Oncology - Abstract
TPS226 Background: Despite recent improvements, management of locally advanced rectal cancer (LARC) remains challenging, and many patients (pts) still experience recurrence. In preclinical models, combining Rego with an anti-PD-1 inhibitor led to superior tumour growth suppression as compared with either treatment alone. In a phase I clinical trial, remarkable results were reported for the combination of Rego and Nivo in advanced MSS colorectal cancer. This synergistic effect is thought to be secondary to the anti-angiogenic effects of Rego and its potential to reduce TAMs, promote M1 macrophage conversion, and down-regulate expression of immunosuppressive factors. Building on these data, we designed a trial of Rego-Nivo with standard SCRT in the neoadjuvant setting of RC. Methods: REGINA is an academic, multicentre, single-arm, phase II trial sponsored by Institut Jules Bordet. Eligible patients are treated according to the following plan: induction phase (Nivo 240 mg IV D1&15, and Rego 80 mg PO D1-14), SCRT (D22-26), consolidation phase (Nivo 240 mg IV D29,43&57, and Rego 80 mg PO D29-49), and surgery (7-8 weeks after SCRT). Key eligibility criteria include age ≥18 years, ECOG PS ≤1, adenocarcinomas below the peritoneal reflection, intermediate-risk, stage II-III tumour (ie, cT3/T4aNany or cT1-2N+, no involvement/threatening of the mesorectal fascia, no involvement of lateral pelvic lymph nodes) irrespective of microsatellite instability status. The primary endpoint is pathological complete response (pCR). Secondary endpoints include, among others, toxicity, compliance to treatment, pathological tumour regression grade, event-free survival, and overall survival. Subjects will be followed for recurrence and survival for 5 years after end of treatment visit. The study follows a Simon’s two-stage design (null hypothesis pCR = 12%, alternative hypothesis pCR = 24%; α= 5%, β= 20%) with a maximum of 60 pts to be enrolled. A safety interim analysis is planned after the first 6 pts have completed treatment. Serial collection of tumour, blood, and stool samples is mandatory at pre-specified time points for exploratory correlative biomarker analyses. The trial is planned to be run at 8-10 centres across Belgium. Study recruitment started in Q1 2021 and is anticipated to complete in Q3 2023. The study is funded by Bayer. Clinical trial information: NCT04503694.
- Published
- 2022
186. SO-27 Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142
- Author
-
Arteid Memaj, H. J. Lenz, E. Van Cutsem, Andrew G. Hill, Ming Lei, Michael A. Morse, Ka Yeung Mark Wong, Bart Neyns, Sandzhar Abdullaev, Michael J. Overman, Thierry André, Massimo Aglietta, Fabio Gelsomino, Scott Kopetz, Michael B. Sawyer, S. Lonardi, Raymond S. McDermott, and Alain Hendlisz
- Subjects
Oncology ,medicine.medical_specialty ,Colorectal cancer ,business.industry ,Low dose ,Checkmate ,Microsatellite instability ,Ipilimumab ,Hematology ,medicine.disease ,Internal medicine ,medicine ,DNA mismatch repair ,Nivolumab ,Previously treated ,business ,medicine.drug - Published
- 2021
187. P-276 Sex and regorafenib toxicity in refractory colorectal cancer: A safety analysis of the RegARd-C trial
- Author
-
Javier Carrasco, Thomas Guiot, Philippe Vergauwe, Giacomo Bregni, Caroline Vandeputte, K. Geboes, Thierry Delaunoit, L. D'Hondt, J. C. Goeminne, Amélie Deleporte, Patrick Flamen, G. Paraskevas, Pashalina Kehagias, Jozef Janssens, Francesco Sclafani, Alain Hendlisz, Monika Peeters, Gauthier Demolin, Stéphane Holbrechts, and J.-L. Van Laethem
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,Colorectal cancer ,Hematology ,medicine.disease ,chemistry.chemical_compound ,Refractory ,chemistry ,Internal medicine ,Regorafenib ,Toxicity ,Medicine ,business - Published
- 2021
188. Editorial: Radioembolization for metastatic colorectal cancer: towards maturity, at last?
- Author
-
Alain Hendlisz and Francesco Sclafani
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,business.industry ,Colorectal cancer ,medicine.medical_treatment ,Liver Neoplasms ,MEDLINE ,medicine.disease ,Embolization, Therapeutic ,Maturity (finance) ,Clinical trial ,Clinical Trials, Phase III as Topic ,Internal medicine ,Carcinoma ,Humans ,Medicine ,Yttrium Radioisotopes ,Embolization ,Colorectal Neoplasms ,business ,Randomized Controlled Trials as Topic - Published
- 2021
189. Anal squamous cell carcinoma: standards of care, new data and ongoing clinical trials
- Author
-
Giunta, Emilio Francesco, primary, Bregni, Giacomo, additional, Hendlisz, Alain, additional, and Sclafani, Francesco, additional
- Published
- 2021
- Full Text
- View/download PDF
190. Clinico‐metabolic characterization improves the prognostic value of histological growth patterns in patients undergoing surgery for colorectal liver metastases
- Author
-
Bohlok, Ali, primary, Duran Derijckere, Ivan, additional, Azema, Hugues, additional, Lucidi, Valerio, additional, Vankerckhove, Sophie, additional, Hendlisz, Alain, additional, Van Laethem, Jean Luc, additional, Vierasu, Irina, additional, Goldman, Serge, additional, Flamen, Patrick, additional, Larsimont, Denis, additional, Demetter, Pieter, additional, Dirix, Luc, additional, Vermeulen, Peter, additional, and Donckier, Vincent, additional
- Published
- 2021
- Full Text
- View/download PDF
191. Prognostic Value of the Pace of Tumor Progression as Assessed by Serial 18F-FDG PET/CT Scan and Liquid Biopsy in Refractory Colorectal Cancer: The CORIOLAN Trial
- Author
-
Tugba Akin Telli, Françoise Rothé, Francesco Sclafani, Caroline Vandeputte, Gabriela Critchi, Silvia Camera, Giacomo Bregni, Chiara Senti, Elena Trevisi, Yacine Wissam, Frédéric Hoerner, Amélie Deleporte, Paraskevas Gkolfakis, Andrea Pretta, Pashalina Kehagias, Patrick Flamen, Alain Hendlisz, Erwin Woff, Thomas Guiot, and Sophia Leduc
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Pace of progression ,Colorectal cancer ,colorectal cancer ,circulating tumor cells ,lcsh:RC254-282 ,Article ,Whole-body metabolically active tumor volume ,03 medical and health sciences ,0302 clinical medicine ,Circulating tumor cell ,Carcinoembryonic antigen ,Internal medicine ,medicine ,pace of progression ,030212 general & internal medicine ,Liquid biopsy ,Imagerie médicale, radiologie, tomographie ,circulating tumor DNA ,Circulating tumor DNA ,biology ,business.industry ,Hazard ratio ,Circulating tumor cells ,Cancer ,Sciences bio-médicales et agricoles ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,medicine.disease ,Cancérologie ,Tumor progression ,030220 oncology & carcinogenesis ,biology.protein ,Sample collection ,business ,whole-body metabolically active tumor volume - Abstract
Introduction: Decision making in refractory colorectal cancer (rCRC) is challenging, with limited data available to predict patient outcome. We conducted a study to assess the pace of cancer progression as a potential prognostic and decision tool. Methods: CORIOLAN was a prospective, single-center, single-arm trial recruiting refractory CRC patients with an ECOG performance status of &le, 1 and an estimated life expectancy of &ge, 12 weeks. 18 fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) scan and blood sample collection were carried out at baseline and after 2 weeks with no cancer treatment given between these timepoints. The primary objective was to evaluate the association between pace of cancer progression as defined by changes of the whole-body metabolically active tumor volume (WB-MATV) and overall survival (OS). Exploratory objectives included evaluation of the prognostic value of circulating cell-free DNA (cfDNA), circulating tumor cells (CTCs) and carcinoembryonic antigen (CEA). Results: 47 eligible patients who had received a median number of 5 (range 2&ndash, 8) prior treatments were enrolled. At the time of analysis, 45 deaths had occurred, with 26% of patients dying within 12 weeks. The median OS was 6.3 months (range 0.4&ndash, 14.3). The median relative delta between WB-MATV at baseline and 2 weeks was +21%. Changes of WB-MATV, however, failed to predict OS (hazard ratio (HR) 1.3, p = 0.383). Similarly, no association was observed between changes of any of the circulating biomarkers investigated and prognosis. By contrast, high WB-MATV (4.2 versus 9.4 months, HR 3.1, p = 0.003), high CEA (4.4 versus 7.0 months, HR 1.9, p = 0.053), high cfDNA (4.7 versus 7.0 months, HR 2.2, p = 0.015) and high CTC count (3.3 versus 7.5 months, HR 6.5, p <, 0.001) at baseline were associated with worse OS. Conclusions: In this study, approximately 1 out of 4 refractory CRC patients who were judged to have a life expectancy >, 12 weeks actually died within 12 weeks. Baseline assessment of WB-MATV, cfDNA, CTCs and CEA, but not early change evaluation of the same, may help to refine patient prognostication and guide management decisions.
- Published
- 2020
- Full Text
- View/download PDF
192. Malignant bowel obstruction: effectiveness and safety of systemic chemotherapy
- Author
-
Joao Glasberg, Tiago Kenji Takahashi, Jorge Sabbaga, Evandro de Azambuja, Alain Hendlisz, David Queiroz Borges Muniz, Rafael Caparica, Rodrigo Canellas, Paulo P. Amaral, Larissa Costa Amorim, Elias Abdo Filho, Daniel Fernandes Saragiotto, Lucas Fernando Uratani, and Milena Mak
- Subjects
medicine.medical_specialty ,Chemotherapy ,education.field_of_study ,Performance status ,Oncology (nursing) ,business.industry ,medicine.medical_treatment ,Population ,Medicine (miscellaneous) ,Retrospective cohort study ,General Medicine ,medicine.disease ,Malignancy ,Bowel obstruction ,03 medical and health sciences ,Medical–Surgical Nursing ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,Clinical endpoint ,030212 general & internal medicine ,business ,education ,Adverse effect - Abstract
ObjectivesAlthough systemic chemotherapy is often administered to patients with malignant bowel obstruction (MBO), its benefit remains unknown. This study assessed the outcomes of patients who received systemic chemotherapy as part of MBO treatment.MethodsFor this retrospective cohort study, data were extracted from records of patients hospitalised due to MBO in a tertiary cancer centre from 2008 to 2020. Eligible patients were not candidates for surgery and received systemic chemotherapy targeting the underlying malignancy causing MBO. Primary objective was to assess patient outcomes after chemotherapy; secondary objectives were rates of intestinal function recovery, hospital discharge and grade ≥3 toxicities. The primary endpoint was overall survival (OS).ResultsA total of 167 patients were included: median age was 55 (18–81) years, 91% had an Eastern Cooperative Oncology Group (ECOG) performance status ≥2, 75.5% had gastrointestinal tumours and 70% were treatment-naive. The median OS after chemotherapy was 4.4 weeks (95% CI 3.4 to 5.5) in the overall population. No OS difference was observed according to treatment line (p=0.24) or primary tumour (p=0.13). Intestinal function recovery occurred in 87 patients (52%), out of whom 21 (24.1%) had a reobstruction. Hospital discharge was possible in 74 patients (44.3%). Grade≥3 adverse events occurred in 26.9% of the patients, and a total of 12 deaths (7%) attributed to toxicities were observed after chemotherapy.ConclusionsMBO was associated with a dismal prognosis in this mostly treatment-naive population. The administration of chemotherapy yielded a significant risk of toxicities, whereas it did not appear to provide any relevant survival benefit in this scenario.
- Published
- 2020
193. Feasibility and clinical impact of routine molecular testing of gastrointestinal cancers at a tertiary centre with a multi-gene, tumor-agnostic, next generation sequencing panel
- Author
-
Thierry Gil, Ligia Craciun, Tugba Akin Telli, Silvia Camera, Chiara Senti, Ahmad Awada, Caroline Vandeputte, Sophia Leduc, Everardo D. Saad, Joseph Kerger, Andrea Pretta, Alain Hendlisz, Martine Piccart-Gebhart, Denis Larsimont, Philippe Aftimos, Amélie Deleporte, Francesco Sclafani, Pieter Demetter, Pashalina Kehagias, Giacomo Bregni, Elena Trevisi, and Tiberio Sticca
- Subjects
medicine.medical_specialty ,business.industry ,High-Throughput Nucleotide Sequencing ,Hematology ,General Medicine ,Multi gene ,DNA sequencing ,030218 nuclear medicine & medical imaging ,Clinical Practice ,03 medical and health sciences ,0302 clinical medicine ,Oncology ,Molecular Diagnostic Techniques ,030220 oncology & carcinogenesis ,Mutation ,medicine ,Feasibility Studies ,Humans ,Radiology, Nuclear Medicine and imaging ,Medical physics ,business ,Value (mathematics) ,Gastrointestinal Neoplasms - Abstract
High-throughput sequencing technologies are increasingly used in research but limited data are available on the feasibility and value of these when routinely adopted in clinical practice.We analyzed all consecutive cancer patients for whom genomic testing by a 48-gene next-generation sequencing (NGS) panel (Truseq Amplicon Cancer Panel, Illumina) was requested as part of standard care in one of the largest Belgian cancer networks between 2014 and 2019. Feasibility of NGS was assessed in all study patients, while the impact of NGS on the decision making was analyzed in the group of gastrointestinal cancer patients.Tumor samples from 1064 patients with varying tumor types were tested, the number of NGS requests increasing over time (Our findings confirm that NGS is feasible in the clinical setting with acceptably low failure rates and rapid turnaround time. In gastrointestinal cancers, however, NGS-based multiple-gene testing adds very little to standard targeted sequencing, and in routine practice the clinical impact of NGS panels including genes which are not routinely recommended by international guidelines remains limited.
- Published
- 2020
194. Novel strategies using modern radiotherapy to improve pancreatic cancer outcomes: toward a new standard?
- Author
-
Alain Hendlisz, Jean-Luc Van Laethem, Luigi Moretti, Jean Closset, Christelle Bouchart, Dirk Van Gestel, and Julie Navez
- Subjects
Oncology ,medicine.medical_specialty ,Pancreatic ductal adenocarcinoma ,heavy-particle radiotherapy ,medicine.medical_treatment ,pancreatic cancer ,Review ,Disease ,lcsh:RC254-282 ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Pancreatic cancer ,medicine ,neoadjuvant therapy ,030212 general & internal medicine ,radiotherapy ,Neoadjuvant therapy ,Chemotherapy ,business.industry ,medicine.disease ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Cancérologie ,Radiation therapy ,Clinical trial ,030220 oncology & carcinogenesis ,stereotactic radiotherapy ,business ,Adjuvant - Abstract
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive solid tumours with an estimated 5-year overall survival rate of 7% for all stages combined. In this highly resistant disease that is located in the vicinity of many radiosensitive organs, the role of radiotherapy (RT) and indications for its use in this setting have been debated for a long time and are still under investigation. Although a survival benefit has yet to be clearly demonstrated for RT, it is the only technique, other than surgery, that has been demonstrated to lead to local control improvement. The adjuvant approach is now strongly challenged by neoadjuvant treatments that could spare patients with rapidly progressive systemic disease from unnecessary surgery and may increase free margin (R0) resection rates for those eligible for surgery. Recently developed dose-escalated RT treatments, designed either to maintain full-dose chemotherapy or to deliver a high biologically effective dose, particularly to areas of contact between the tumour and blood vessels, such as hypofractionated ablative RT (HFA-RT) or stereotactic body RT (SBRT), are progressively changing the treatment landscape. These modern strategies are currently being tested in prospective clinical trials with encouraging preliminary results, paving the way for more effective treatment combinations using novel targeted therapies. This review summarizes the current literature regarding the use of RT for the treatment of primary PDAC, describes the limitations of conventional RT, and discusses the emerging role of dose-escalated RT and heavy-particle RT., SCOPUS: re.j, info:eu-repo/semantics/published
- Published
- 2020
195. Editorial: Adjuvant chemotherapy for gastrointestinal cancers: we can do much better
- Author
-
Francesco Sclafani and Alain Hendlisz
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Chemotherapy ,Adjuvant chemotherapy ,business.industry ,medicine.medical_treatment ,MEDLINE ,Chemotherapy, Adjuvant ,Internal medicine ,medicine ,Humans ,business ,Adjuvant ,Gastrointestinal Neoplasms - Published
- 2020
196. The lack of selection criteria for surgery in patients with non-colorectal non-neuroendocrine liver metastases
- Author
-
Jean-Luc Van Laethem, Fikri Bouazza, Valerio Lucidi, Desislava Germanova, Ali Bohlok, Alain Hendlisz, Vincent Donckier, and Ali Daher
- Subjects
Adult ,Male ,medicine.medical_specialty ,Population level ,Population ,Clinical Decision-Making ,lcsh:Surgery ,Individual ,Prognostic ,lcsh:RC254-282 ,Disease-Free Survival ,Non-colorectal ,Liver metastases ,Text mining ,Surgical oncology ,Medicine ,Hepatectomy ,Humans ,In patient ,education ,Chirurgie ,Selection ,Selection (genetic algorithm) ,Aged ,Aged, 80 and over ,education.field_of_study ,business.industry ,Patient Selection ,Research ,Liver Neoplasms ,lcsh:RD1-811 ,Middle Aged ,medicine.disease ,Prognosis ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Primary tumor ,Surgery ,Cancérologie ,Survival Rate ,Non colorectal ,Oncology ,Liver ,Female ,Neoplasm Recurrence, Local ,business ,Non-neuroendocrine - Abstract
Background: The benefit of surgery in patients with non-colorectal non-neuroendocrine liver metastases (NCRNNELM) remains controversial. At the population level, several statistical prognostic factors and scores have been proposed but inconsistently verified. At the patient level, no selection criteria have been demonstrated to guide individual therapeutic decision making. We aimed to evaluate potential individual selection criteria to predict the benefit of surgery in patients undergoing treatment for NCRNNELM. Methods: Data for 114 patients undergoing surgery for NCRNNELM were reviewed. In this population, we identified an early relapse group (ER), defined as patients with unresectable recurrence < 1 year postoperatively who did not benefit from surgery (N = 28), and a long-term survival group (LTS), defined as patients who were recurrence-free ≥ 5 years postoperatively and benefited from surgery (N = 20). Clinicopathologic parameters, the Association Française de Chirurgie (AFC) score, and a modified 4-point Clinical Risk Score (mCRS) (excluding CEA level) were analyzed and compared between LTS and ER groups. Results: The majority of patients were female and a majority had an ASA score ≤ 2 at the time of liver surgery. The median age was 55 years. Almost half of the patients (46%) presented with a single-liver metastasis. Intermediate- and low-risk AFC scores represented 40% and 60% of the population, respectively. Five- and 10-year overall survival (OS) and disease-free survival (DFS) rates were 56% and 27%, and 30% and 12%, respectively. Negative prognostic factors were the size of liver metastases > 50 mm and delay between primary and NCRNNELM, SCOPUS: ar.j, info:eu-repo/semantics/published
- Published
- 2020
197. Nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Two-year clinical update
- Author
-
Lenz, Heinz-Josef, Lonardi, Sara, Zagonel, Vittorina, Van Cutsem, Eric, Limon, M. Luisa, Wong, Mark, Hendlisz, Alain, Aglietta, Massimo, Garcia-Alfonso, Pilar, Neyns, Bart, Gelsomino, Fabio, Cardin, Dana Backlund, Dragovich, Tomislav, Shah, Usman, Yang, Jing, Ledeine, Jean-Marie, Overman, Michael J., Medical Oncology, Clinical sciences, Laboratory of Molecular and Medical Oncology, Laboratory of Molecullar and Cellular Therapy, and Faculty of Economic and Social Sciences and Solvay Business School
- Abstract
Background: In the phase 2 CheckMate 142 trial, NIVO + low-dose IPI had robust, durable clinical benefit and was well tolerated as 1L therapy for MSI-H/dMMR mCRC (median follow-up 13.8 months [mo; range, 9–19]; Lenz et al. Ann Oncol 2018;29:LBA18). Longer follow-up is presented here. Methods: Patients (pts) with MSI-H/dMMR mCRC and no prior treatment for metastatic disease received NIVO 3 mg/kg Q2W + low-dose IPI 1 mg/kg Q6W until disease progression or discontinuation. The primary endpoint was investigator-assessed (INV) objective response rate (ORR) per RECIST v1.1. Results: In 45 pts with median follow-up of 29.0 mo, ORR (95% CI) increased to 69% (53–82) (Table) from 60% (44.3–74.3); complete response (CR) rate increased to 13% from 7%. The concordance rate of INV and blinded independent central review was 89%. Median duration of response (DOR) was not reached (Table). Median progression-free survival (PFS) and overall survival (OS) were not reached, and 24-mo rates were 74% and 79%, respectively (Table). Nineteen pts discontinued study treatment without subsequent therapy. An analysis of tumor response post discontinuation will be presented. Ten (22%) pts had grade 3–4 treatment-related adverse events (TRAEs); 3 (7%) had grade 3–4 TRAEs leading to discontinuation. Conclusions: NIVO + low-dose IPI continued to show robust, durable clinical benefit with a deepening of response, and was well tolerated with no new safety signals identified with longer follow-up. NIVO + low-dose IPI may represent a new 1L therapy option for pts with MSI-H/dMMR mCRC.
- Published
- 2020
198. MOMENTUM: A Phase I Trial Investigating 2 Schedules of Capecitabine With Aflibercept in Patients With Gastrointestinal and Breast Cancer
- Author
-
Silvia Camera, Ahmad Awada, Lieveke Ameye, Tugba Akin Telli, Amélie Deleporte, Giacomo Bregni, Elena Trevisi, Martine Piccart-Gebhart, Francesco Sclafani, Laura Polastro, Aline Kayumba, Alain Hendlisz, Andrea Pretta, and Andrea Gombos
- Subjects
Oncology ,Adult ,Male ,medicine.medical_specialty ,Maximum Tolerated Dose ,Colorectal cancer ,Recombinant Fusion Proteins ,Breast Neoplasms ,Anorexia ,Severity of Illness Index ,Capecitabine ,03 medical and health sciences ,0302 clinical medicine ,Breast cancer ,Stomach Neoplasms ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Medicine ,Humans ,Dosing ,Adverse effect ,Response Evaluation Criteria in Solid Tumors ,Aflibercept ,Aged ,Dose-Response Relationship, Drug ,business.industry ,Gastroenterology ,Cancer ,Middle Aged ,medicine.disease ,Receptors, Vascular Endothelial Growth Factor ,Drug Resistance, Neoplasm ,030220 oncology & carcinogenesis ,Hypertension ,Feasibility Studies ,030211 gastroenterology & hepatology ,Female ,Hand-Foot Syndrome ,medicine.symptom ,business ,Colorectal Neoplasms ,medicine.drug - Abstract
Background Although data from preclinical and clinical studies provide a strong rationale for combining capecitabine with anti-angiogenic agents, clinical development of this fluoropyrimidine in combination with aflibercept has lagged behind other treatments. We conducted a nonrandomized, noncomparative, 2-arm, phase I trial to address this unmet need. Patients and Methods Patients with chemorefractory gastrointestinal and breast cancer were sequentially recruited into a continuous (Arm A, starting dose 1100 mg/m2/day) or intermittent (Arm B, 2 weeks on/1 week off, starting dose 1700 mg/m2/day) capecitabine dosing arm. Aflibercept was administered at a flat dose of 6 mg/kg every 3 weeks in both arms. A classical 3 + 3, dose-escalation design was used. The primary objective was to establish the maximum tolerated dose, dose-limiting toxicities (DLTs), and recommended dose for phase II trials. Results Thirty-eight eligible patients were recruited of whom 33 were assessable for DLTs (15 in arm A and 18 in arm B). Fourteen had colorectal cancer, 8 gastric cancer, and 11 breast cancer. DLTs included grade 2 hand-foot syndrome, grade 2 anorexia considered unacceptable by the patient, and grade 3 hypertension. The recommended dose for phase II trials for capecitabine was established at 1300 mg/m2/day in Arm A and 2500 mg/m2/day in Arm B with treatment-related grade ≥ 3 adverse events occurring in 47% and 50% of patients, respectively. Among 26 assessable patients, the objective response rate was 15.4% in Arm A and 7.7% in Arm B. Conclusion Combining capecitabine with aflibercept is feasible and associated with a manageable safety profile and some anti-tumor activity in patients with chemorefractory gastrointestinal and breast cancer.
- Published
- 2020
199. Fat density is a novel prognostic marker in patients with esophageal cancer
- Author
-
Caroline Vandeputte, Patrick Flamen, Thomas Guiot, Vincent Donckier, Pieter Demetter, Amélie Deleporte, Lieveke Ameye, André Van Gossum, Alain Hendlisz, Francesco Sclafani, Cynthia Wenglinski, and Maelle Anciaux
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Esophageal Neoplasms ,Endocrinology, Diabetes and Metabolism ,Population ,Esophageal cancer ,Adipose tissue ,030209 endocrinology & metabolism ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Weight loss ,Fluorodeoxyglucose F18 ,Internal medicine ,Positron Emission Tomography Computed Tomography ,medicine ,Adipose tissue density ,Humans ,Risk factor ,education ,Body mass composition ,Retrospective Studies ,Fluorodeoxyglucose ,education.field_of_study ,030109 nutrition & dietetics ,Nutrition and Dietetics ,business.industry ,Cancer ,CT-scan ,Sciences bio-médicales et agricoles ,medicine.disease ,Prognosis ,Cohort ,medicine.symptom ,business ,medicine.drug - Abstract
Background & aims: While long-term obesity is a well-known risk factor for esophageal adenocarcinoma (ADC), recent weight loss represents a significant concern in esophageal cancer (EC), in relation with dysphagia and disease aggressiveness. These phenomenons may diversely impact the adipose tissue density, suggested in other cancer settings as an important prognostic biomarker. The analysis of body mass composition (BMC) parameters, including adipose tissue attenuation is studied here in a population of EC operated with curative intent. Methods: BMC was retrospectively evaluated on Computed-Tomography (CT)-scan images from fluorodeoxyglucose (FDG)-positron-emitting (PET)/CT scans performed as a diagnostic procedure in a cohort of 145 EC patients operated with curative intent The mean subcutaneous (SFD) and visceral fat (VFD) density along with the index (area/height2) (SF index (SFI), VF index (VFI)) were assessed on two adjacent slides at the third lumbar vertebra level by two independent investigators. Overall survival (OS) was calculated from the date of the baseline FDG-PET/CT scan. Results: Inter-observer correlations are excellent for all BMC parameters (r = 0.94–0.99). As expected, weight loss is associated with worse outcome. We show that low SFD (HR 0.5 (95% CI: 0.3–0.7), p < 0.001) and low VFD (HR 0.6 (95% CI: 0.4–0.9), p = 0.04) at diagnosis are associated with better OS. In contrast, body mass index (BMI) fails to show any relevance in predicting survival. Conclusions: Adipose tissue density is an important prognostic factor in EC., SCOPUS: ar.j, info:eu-repo/semantics/published
- Published
- 2020
200. Nivolumab plus low-dose ipilimumab as first-line therapy in microsatellite instability-high/DNA mismatch repair deficient metastatic colorectal cancer: Clinical update
- Author
-
Jean-Marie Ledeine, Massimo Aglietta, Dana Backlund Cardin, Eric Van Cutsem, Ka Yeung Mark Wong, M. Luisa Limon, Alain Hendlisz, Andrea Spallanzani, Pilar García-Alfonso, Bart Neyns, Michael J. Overman, Tomislav Dragovich, Ajlan Atasoy, Usman Shah, Sara Lonardi, Vittorina Zagonel, Heinz-Josef Lenz, Medical Oncology, Clinical sciences, Laboratory for Medical and Molecular Oncology, and Laboratory of Molecullar and Cellular Therapy
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Colorectal cancer ,business.industry ,Low dose ,Microsatellite instability ,Ipilimumab ,medicine.disease ,03 medical and health sciences ,0302 clinical medicine ,First line therapy ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,Microsatellite ,DNA mismatch repair ,Nivolumab ,business ,030215 immunology ,medicine.drug - Abstract
11 Background: In the phase 2 CheckMate 142 trial, nivolumab plus low-dose ipilimumab provided robust and durable clinical benefit and was well tolerated as first-line therapy for microsatellite instability-high/DNA mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) (Lenz et al. Ann Oncol 2018;29:LBA18). Longer follow-up data will be presented. Methods: Patients with MSI-H/dMMR mCRC and no prior treatment for metastatic disease received nivolumab 3 mg/kg every 2 weeks plus low-dose ipilimumab 1 mg/kg every 6 weeks until disease progression or discontinuation. The primary endpoint was investigator-assessed objective response rate (ORR). Results: For all 45 patients (median follow-up was 13.8 months), ORR was 60% (95% CI 44.3–74.3). Responses were consistent with the overall population across subgroups including age, Eastern Cooperative Oncology Group (ECOG) performance status, prior adjuvant/neoadjuvant therapy, and mutation status (Table). Seven patients (16%) had grade 3–4 treatment-related adverse events; 3 (7%) had any grade treatment-related adverse events leading to discontinuation. Updated response, survival, and safety data after a longer follow-up (median 19.9 months) will be presented. Conclusions: Nivolumab plus low-dose ipilimumab demonstrated robust and durable clinical benefit and was well tolerated. Evaluated subgroups had responses consistent with the overall population. Nivolumab plus low-dose ipilimumab may represent a new first-line treatment option for patients with MSI-H/dMMR mCRC. Clinical trial information: NCT02060188. [Table: see text]
- Published
- 2020
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.